Protocol Ledger

NCT06547489 · Phase II · RECRUITING

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Interventional Phase II clinical trial protocol NCT06547489 sponsored by Syndeio Biosciences in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-03 Enrollment: 164 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06547489
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)164 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06547489
Protocol FieldVerified Registry Value
NCT IdentifierNCT06547489
Consolidated Lead SponsorSyndeio Biosciences
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment164 participants (ESTIMATED)
Registered Start Date2025-02-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06547489
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->
Clinical Neuroscience Solutions, Inc.Jacksonville, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI